UK’s NICE Recommends Bosutinib for Chronic Myeloid Leukemia

The U.K. National Institute for Health and Care Excellence (NICE) has recommended bosutinib for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia after working with the drug’s manufacturer – Pfizer Inc. – to overhaul the pricing in the United Kingdom. Previously, the drug was only available to patients through the Cancer Drugs Fund because of concerns about its cost-effectiveness, but it is now routinely available through the U.K.’s National Health Service.

This is the first treatment to be reconsidered for coverage by the National Health Service after the organization decided to reconsider the drugs available only through the Cancer Drugs Fund earlier this year.

Sources: Bloomberg News, July 6, 2016; Reuters, July 6, 2016.